Current Report Filing (8-k)
August 22 2022 - 4:31PM
Edgar (US Regulatory)
0001837412
false
0001837412
2022-08-16
2022-08-16
0001837412
SLGC:ClassCommonStock0.0001ParValuePerShareMember
2022-08-16
2022-08-16
0001837412
SLGC:WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember
2022-08-16
2022-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 16, 2022
SomaLogic,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40090 |
|
85-4298912 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
2945
Wilderness Place, Boulder, Colorado |
|
80301 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (303) 625-9000
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under
any of the following provisions (see General Instruction A.2 below):
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
Class
A common stock, $0.0001 par value per share |
|
SLGC |
|
The
Nasdaq Stock Market LLC |
Warrants,
each exercisable for one share of Class A common stock at an exercise price of $11.50 per share |
|
SLGCW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On August 16, 2022, SomaLogic, Inc. (the “Company”) announced
internally that Melody Harris, President and Chief Operating Officer of the Company, will be leaving the Company, effective August 31,
2022. Upon separation, Ms. Harris will receive benefits as set forth in “EXECUTIVE COMPENSATION—Executive Employment Arrangements—Enhanced
Severance” in the Company’s proxy statement dated April 25, 2022. The Company’s management team and the Board of
Directors would like to extend their thanks to Ms. Harris for her years of service to the Company.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. |
|
Description |
|
|
|
104 |
|
Cover Page Interactive Data File |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SomaLogic,
Inc. |
|
(Registrant) |
|
|
|
|
By: |
/s/
Ruben Gutierrez |
|
Name:
|
Ruben
Gutierrez |
|
Title:
|
General
Counsel |
August
22, 2022
2
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Jun 2024 to Jul 2024
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Jul 2023 to Jul 2024